Inovio pharmaceuticals stock.

View Inovio Pharmaceuticals, Inc INO investment & stock information. Get the latest Inovio Pharmaceuticals, Inc INO detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Nov 28, 2023 · The average trading volume of INO on November 28, 2023 was 3.45M shares. INO) stock’s latest price update. Inovio Pharmaceuticals Inc (NASDAQ: INO)’s stock price has decreased by -3.07 compared to its previous closing price of 0.41. However, the company has seen a -5.38% decrease in its stock price over the last five trading sessions. Inovio Pharmaceuticals (INO) stock price prediction is 2.5270197612807 USD. The Inovio Pharmaceuticals stock forecast is 2.5270197612807 USD for 2024 ...The stock price of Inovio Pharmaceuticals, a biotechnology company focused on synthetic DNA products for treating cancers and infectious diseases, has seen a large fall of 17% over the last month ...

Inovio Pharmaceuticals, Inc. Common Stock (INO) 0 Add to Watchlist Add to Portfolio Quotes Summary Real-Time Key Data Bid Price and Ask Price The bid & ask refers to the price that an...Inovio Pharmaceuticals 's revenue in 2023 is $854,026.On average, 3 Wall Street analysts forecast INO's revenue for 2023 to be $227,397,691, with the lowest INO revenue forecast at $191,090,497, and the highest INO revenue forecast at $272,986,424.

Find real-time INO - Inovio Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. ... Inovio Pharmaceuticals Inc (NASDAQ:INO) 0.4291. Delayed Data. As of Nov 17 ...

Nov 16, 2023 · Future criteria checks 2/6. Inovio Pharmaceuticals is forecast to grow earnings and revenue by 36.7% and 80.4% per annum respectively while EPS is expected to grow by 46.7% per annum. Stock analysis for Inovio Pharmaceuticals Inc (INO:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.ROBERT J. JUBA JR. “INOVIO’s team has extensive experience manufacturing DNA medicines and a proven track record of producing them at unprecedented speeds.”. “INOVIO’s CELLECTRA® intramuscular and intracellular smart devices have allowed us to deliver our optimized DNA plasmids directly into cells in the body to produce immune responses. See Inovio Pharmaceuticals, Inc. (INO) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.Inovio Pharmaceuticals. Market Cap. $111M. Today's Change. (2.77%) $0.01. Current Price. Price as of November 24, 2023, 1:00 p.m. ET. You’re reading a free article with opinions that may differ ...

Stock analysis for Inovio Pharmaceuticals Inc (INO:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Inovio Pharmaceuticals Inc. closed $1.59 below its 52-week high ($1.99), which the company reached on January 13th. The stock outperformed some of its competitors …

The stock price of Inovio Pharmaceuticals, a biotechnology company focused on synthetic DNA products for treating cancers and infectious diseases, has seen a large fall of 17% over the last month ...Inovio Pharmaceuticals is easily one of the most volatile stocks on the market right now. Even relatively mild news, such as its recent Q4 results, was enough to send the stock plunging 28%.Inovio Pharmaceuticals (INO 2.77%) Q2 2023 Earnings Call Aug 09, 2023, 4:30 p.m. ET. Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared Remarks: Operator. Good day, and ...Inovio Pharmaceuticals, Inc. stockholders' equity: Preferred stock—par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December 31, 2021 and 20204 Mar 2020 ... Shares of Inovio Pharmaceuticals Inc., the genetic vaccine company, hit a four-year high Wednesday, rising as much as 16% to $9.40 a share ...May 15, 2023 · Inovio Pharmaceuticals (INO) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which ... Inovio Pharmaceuticals Inc. closed $1.59 below its 52-week high ($1.99), which the company reached on January 13th. The stock outperformed some of its competitors …

The consensus among analysts is that Inovio Pharmaceuticals Inc (INO) is a Hold stock at the moment, with a recommendation rating of 3.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 3 out of 3 have rated it as a Hold, with 0 advising it as a Buy. 0 have rated the stock as Underweight.Inovio Pharmaceuticals, Inc. Common Stock (INO) 0 Add to Watchlist Add to Portfolio Quotes Summary Real-Time Key Data Bid Price and Ask Price The bid & ask refers to the price that an... Research & Development Center. 10480 Wateridge Circle San Diego, CA 92121 Phone: 858-597-6006Find out the direct holders, institutional holders and mutual fund holders for Inovio Pharmaceuticals, Inc. (INO).BLUE BELL, Pa., May 30, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that its previously announced 1-for-4 reverse stock split shall become effective at 5 P.M ...WebInovio Pharmaceuticals Inc INO Morningstar Rating Unlock Stock XNAS Rating as of Nov 30, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation...

View Inovio Pharmaceuticals, Inc INO investment & stock information. Get the latest Inovio Pharmaceuticals, Inc INO detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.As of June 30, 2022, Inovio had 247.5 million shares of common stock outstanding and 267.8 million shares of common stock outstanding on a fully diluted basis. Total operating expenses were $104.9M.

Inovio Pharmaceuticals: Implied upside of 434%. But the crème de la crème of upside opportunity, at least on this list, is clinical-stage biotech stock Inovio Pharmaceuticals (INO 0.96%).WebFDA Lifts Partial Clinical Hold on INNOVATE Phase 3 Segment INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-associated diseases, today announced that the U.S. Food and Drug Administration …1 Mei 2020 ... Inovio Pharmaceuticals' stock has climbed higher and higher over the past month since it said it was working on a speedy COVID-19 vaccine.10 Okt 2023 ... Inovio Pharmaceuticals (INO) shares rise after FDA issued positive feedback on its plans to obtain marketing nod for lead asset against a ...On eToro, you can buy $INO or other stocks and pay ZERO commission! Follow Inovio Pharmaceuticals Inc share price and get more information. Terms apply.Agenus, Inovio Pharmaceuticals, and Roivant Sciences are three of the biggest beneficiaries of the industrywide trend. ... Inovio's stock was higher by 10.6%, ...Web

Aug 9, 2023 · Preparing to initiate pivotal Phase 3 trial of INO-3107 in adult RRP patients in first quarter of 2024; INO-3107 received Orphan Drug Designation from European Commission in second quarter Scaling resources and headcount to align with strategic focus on INO-3107 and late-stage clinical candidates closest to market and with greatest opportunity to deliver on the promise of DNA medicines for ...

Inovio Pharmaceuticals. Market Cap. $111M. Today's Change. (2.77%) $0.01. Current Price. Price as of November 24, 2023, 1:00 p.m. ET. You’re reading a free article with opinions that may differ ...

Inovio Pharmaceuticals, Inc. 0.4014-0.0086 ... A stock sale "will shine a spotlight on the business model and financials" of the fast-fashion giant about which little is known, said one analyst. ...Dec 30, 2020 · Inovio Pharmaceuticals (INO-5.34%) has given different groups of investors some wildly varying stock performances this year. If you bought its shares at the beginning of 2020, your investment is ... Inovio Pharmaceuticals is an American biotechnology company focused on the discovery, development, ... Inovio in August 2020, claiming it exaggerated evidence of its coronavirus vaccine's efficacy in order to boost its stock price. License of electroporation deviceFeb 28, 2023 · On March 1, Inovio Pharmaceuticals will release figures for the most recent quarter. Wall Street analysts predict losses per share of $0.168. Watch Inovio Pharmaceuticals stock price in real-time ... Contact Us U.S. markets close in 3 hours 37 minutes +233.26(+0.65%) +40.71 Russell 2000 +40.80(+2.26%) +0.37(+0.49%) Gold (+1.13%) Inovio Pharmaceuticals, Inc. (INO) NasdaqCM - NasdaqCM Real Time...The Inovio Pharmaceuticals stock price gained 4.20% on the last trading day (Thursday, 30th Nov 2023), rising from $0.378 to $0.394.During the last trading day the stock fluctuated 6.38% from a day low at $0.371 to a day high of $0.395.The price has fallen in 6 of the last 10 days but is still up by 3.68% over the past 2 weeks. Volume fell on the …ROBERT J. JUBA JR. “INOVIO’s team has extensive experience manufacturing DNA medicines and a proven track record of producing them at unprecedented speeds.”. “INOVIO’s CELLECTRA® intramuscular and intracellular smart devices have allowed us to deliver our optimized DNA plasmids directly into cells in the body to produce immune responses. Background Additional SARS-CoV-2 vaccines that are safe and effective as primary vaccines and boosters remain urgently needed to combat the COVID-19 pandemic. We describe the safety and durability of the immune responses following two primary doses and a homologous booster dose of an investigational DNA vaccine (INO-4800) targeting …Web

Shares of Inovio Pharmaceuticals ... Inovio's stock closed at $1.56 on Friday, then opened on Monday at $1.63. its stock rose to as high as $1.865 shortly before the close and finished the day at ...Mar 1, 2023 · As of December 31, 2022, INOVIO had 253.1 million common shares outstanding and 271.0 million common shares outstanding on a fully diluted basis, after giving effect to the exercise, vesting, and ... Cost-saving measures include 11% headcount reduction Annual savings expected to be approximately $4.3 million Data readouts expected in first quarter of 2023 for key programs including INO-3107 for RRP and VGX-3100 for cervical HSIL INOVIO ( NASDAQ : INO ), a biotechnology company focused on developing and commercializing …Inovio Pharmaceuticals saw a decline in short interest in the month of October. As of October 31st, there was short interest totaling 24,940,000 shares, a decline of 3.0% from the previous total of 25,710,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are ...Instagram:https://instagram. when does iphone pre order start3 dollar stockshbl habib banknyse burl As the deadly new virus spread globally, Inovio Pharmaceuticals, a small biotech company in Pennsylvania, rushed to develop a vaccine. After announcing promising early results, Inovio’s stock ... net power stockretl Agenus, Inovio Pharmaceuticals, and Roivant Sciences are three of the biggest beneficiaries of the industrywide trend. ... Inovio's stock was higher by 10.6%, ...Web george clooney tequila casamigos Feb 16, 2023 · Inovio Pharmaceuticals, Inc. 0.4014-0.0086 ... A stock sale "will shine a spotlight on the business model and financials" of the fast-fashion giant about which little is known, said one analyst. ... Shares of Inovio Pharmaceuticals (INO-4.71%) ... In the Tweet, Citron Research claims Inovio's stock will fall back to $5, which would be a significant drop from its current levels. The biotech's ...INVESTORS. & MEDIA. Loading... INOVIO is a clinical stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases.